**ISAP Principal Investigators**

**M. Douglas Anglin, Ph.D.**

M. Douglas Anglin (Ph.D.; Social Psychology, UCLA, 1980) was the Founding Director of the UCLA Drug Abuse Research Center (1984–1997) and was an Associate Director of UCLA Integrated Substance Abuse Programs (ISAP) from 1999 to 2010. He is currently a Senior Advisor in the Department of Psychiatry and Biobehavioral Sciences. Dr. Anglin has been conducting research on substance abuse epidemiology, etiology, treatment evaluation, and social policy since 1972. He has been Principal Investigator on more than 25 federally funded research studies and on numerous state- and foundation-supported projects. He has been the author or co-author of more than 225 published articles. Dr. Anglin has served as an advisor to many national treatment evaluation studies, including the Drug Abuse Treatment Outcome Study and the Federal Bureau of Prisons Drug Programs Evaluation Project. He has also served as consultant to the following agencies: National Institute on Drug Abuse, Office of National Drug Control Policy, Center for Substance Abuse Treatment, National Academy of Sciences Institute of Medicine, National Institute of Justice, California Youth Authority and Departments of Alcohol and Drug Programs and Corrections, and Los Angeles County Alcohol and Drug Program Administration. *doug\_anglin@hotmail.com*

### Mary-Lynn Brecht, Ph.D.

Mary-Lynn Brecht, Ph.D., Research Statistician. Dr. Brecht is a researcher and statistical support specialist for the UCLA Integrated Substance Abuse Programs. She is currently conducting a long-term follow-up of methamphetamine users to study use and recovery trajectories. Topics of recent projects have included HIV risk behaviors among methamphetamine users, long-term outcomes of treatment for methamphetamine use, and needs assessment among service providers for technical assistance and training related to problem gambling. She directs the Statistical Support core for the ISAP Center for Advancing Longitudinal Drug Abuse Research. She is an adjunct professor in the UCLA School of Nursing, where she also directs the Research Office Design and Data Core. She has had extensive training and experience in the development/adaptation, application, and integration of quantitative research methodologies, particularly those for longitudinal analyses, with emphasis in the areas of drug-abuse, health systems, and treatment evaluation research.

### ****William M. Burdon, Ph.D.****

Dr. Burdon has been with ISAP for 15 years. He has served as the Principal Investigator of two NIDA-funded studies: a 4-year study that tested the impact of a behavioral reinforcement intervention on inmate engagement in prison-based substance abuse treatment and a 5-year study that tested the differential effectiveness of long-term residential versus intensive outpatient prison-based substance abuse treatment. He is also a Co-Investigator at the Pacific Coast Research Center of NIDA’s Criminal Justice Drug Abuse Treatment Studies 2 (CJ-DATS 2) collaborative. He was previously the Project Director of two multi-site evaluation studies of prison-based therapeutic community substance abuse treatment programs (1998-2004), funded by the California Department of Corrections (CDC). Dr. Burdon’s areas of expertise include substance abuse treatment and corrections policy, contingency management in substance abuse treatment settings, sex offender treatment, and HIV/AIDS among incarcerated and post-incarcerated populations, and he is experienced in both quantitative and qualitative research methodologies. Dr. Burdon has authored publications on prison-based substance abuse treatment, contingency management, sanctions and incentives in prison-based substance abuse treatment programs, and organizational and systems aspects of substance abuse treatment with criminal justice populations and within correctional settings.

### ****Desirée Crèvecoeur-MacPhail, Ph.D.****

**Desirée Crèvecoeur-MacPhail, Ph.D.,**received her doctorate from Claremont Graduate University in Social Psychology and master's degree in clinical psychology from Pepperdine University. Throughout her work at UCLA ISAP, she has been responsible for examining engagement and retention as well as client outcomes, and she has designed research reports that have assisted Los Angeles County in performance management. Her role as Principal Investigator of the Los Angeles County Evaluation System (LACES) has allowed her to implement and assess small pilot projects that have helped move the county closer to a performance-based management system. Her involvement with treatment providers benefited the study as she served as a critical liaison to the treatment community. In addition, she has designed and implemented evaluation programs; supervised staff; addressed all correspondence from the county, commissions, and external sources; coordinated and chaired meetings with county and state officials, treatment providers, and other stakeholders; and composed reports, articles, and newsletters.

### Daniel Dickerson, D.O., M.P.H.

Daniel Dickerson, D.O., M.P.H., Inupiaq, is an addiction psychiatrist and Assistant Research Psychiatrist at UCLA Integrated Substance Abuse Programs (ISAP). He also provides psychiatric and substance abuse services at United American Indian Involvement (UAII) in Los Angeles. His research focuses on substance abuse and HIV among American Indians/Alaska Natives and on the development of culturally relevant substance abuse treatments for American Indians/Alaska Natives. He is a Co-Principal Investigator on an R-01 National Institutes of Health (NIH)-funded grant, “Motivational Interviewing and Culture for Urban Native American Youth (MICUNAY),” an alcohol and drug prevention research project for urban Native American youth. He is also the Principal Investigator on an R-21 NIH-funded research grant, “Drum-Assisted Recovery Therapy for Native Americans (DARTNA),” a substance abuse treatment program utilizing drumming for Native Americans. He is also the Principal Investigator on “Strengthening the Circle,” an HIV prevention program for urban Native Americans. This study was funded through a sub-award from an R25 NIMH-funded program, the Indigenous HIV/AID Research Training (IHART) program, at the University of Washington.

### David Farabee, Ph.D.

David Farabee, Ph.D., is Professor-in-Residence of Psychiatry and Biobehavioral Sciences at the University of California, Los Angeles, and a Principal Investigator at UCLA Integrated Substance Abuse Programs (ISAP). Prior to this, he served as lead analyst for criminal justice research at the Texas Commission on Alcohol and Drug Abuse (1992–1995), and as Assistant Professor of Psychiatry and Research Scientist at the University of Kentucky Center on Drug and Alcohol Research (1995–1997). Dr. Farabee has published in the areas of substance abuse, adult and juvenile crime, HIV/AIDS, and offender treatment, was co-editor of the books *Treatment of Drug Offenders* (2002; New York: Springer) and *Treating Addicted Offenders: A Continuum of Effective Practices*, Volumes I and II (2004, 2007; New York: Civic Research Institute), author of *Rethinking Rehabilitation: Why Can’t We Reform Our Criminals?* (2005; Washington, DC: AEI Press), and is co-editor of the Offender Programs Report.

### Thomas E. Freese****,**** Ph.D.

Thomas E. Freese**,** Ph.D. (Clinical Psychology, California School of Professional Psychology, 1995), is currently the Director of Training for UCLA ISAP and the Principal Investigator and Director of the Pacific Southwest Addiction Technology Transfer Center (PSATTC). Dr. Freese has served as Principal Investigator on projects funded by the California Department of Alcohol and Drug Programs to train providers to implement screening, brief intervention, and referral to treatment (SBIRT). Dr. Freese has also led several large projects that assist providers in implementing integrated treatment for co-occurring mental health and substance use disorders. He has been a featured presenter at conferences and meetings nationally and internationally on the impact and treatment of methamphetamine and opioid dependence. In addition, Dr. Freese has served as the Project Director on a number of studies including research on methamphetamine use. He has worked in the addiction field since 1983 and has developed and conducted trainings in 45 states and internationally, providing training and workshops for clinicians-in-training at the all levels.

### Suzette Glasner-Edwards, Ph.D.

Suzette Glasner-Edwards, Ph.D., is a licensed clinical psychologist and a Principal Investigator at UCLA Integrated Substance Abuse Programs. She earned her B.A. in psychology from UCLA and her Ph.D. in psychology at the University of Minnesota. Subsequently, she completed her postdoctoral training at UCSD and the San Diego VA in the study and practice of psychotherapy for addictions. Dr. Glasner-Edwards has extensive clinical and research background in the use of cognitive-behavioral, motivational, and mindfulness-based interventions for adults who have substance use disorders with and without concurrent mental illness. Dr. Glasner-Edwards teaches these therapy techniques to psychiatry residents and psychologists in postdoctoral training at UCLA. A recipient of a career development award from NIDA, Dr. Glasner-Edwards’ current research focuses on developing technology-assisted psychosocial interventions and evaluating treatment outcomes for drug abusing adults with co-occurring psychiatric illness (with a particular focus on depression). She has also conducted research on pharmacological treatments for stimulant users with depression. Her interests include psychological and pharmacological intervention development and outcome evaluation for substance abusers with co-occurring psychiatric and medical conditions (e.g., HIV), the clinical course of psychiatric illness in individuals with alcohol and/or drug use disorders, mechanisms of action or “key ingredients” of psychotherapy, and risk factors for mental illness among substance abusers.

## Rachel Gonzales, Ph.D.

Rachel Gonzales, Ph.D., M.P.H., is an Associate Research Psychologist at the UCLA Integrated Substance Abuse Programs. She has training in public health, psychology, and addiction medicine. Trained in both qualitative and quantitative research methodologies, her research focuses on the application of behavioral theories to understand the etiology and maintenance of substance use risk behaviors among diverse adolescent and young adult populations. Her research practice focuses on intervention development and recovery for adolescent and young adult populations. She also has extensive research experience with brief intervention and continuing care approaches for substance abuse recovery among youth. She currently is the PI on a NIDA-funded K01 to develop and test the utility of a continuing care intervention for recovery support for youth using mobile based text-messaging.

### Christine E. Grella, Ph.D.

Christine E. Grella, Ph.D., is a Professor of Psychiatry and Biobehavioral Sciences at the Integrated Substance Abuse Programs (ISAP), Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, and Co-Director of ISAP. Her research focuses on the intersection of multiple service delivery systems, including substance abuse treatment, mental health, child welfare, health services, HIV services, and criminal justice. Her work has examined the relationship of service delivery to treatment outcomes, focusing on treatment for women, adolescents, individuals in the criminal justice system, and individuals with co-occurring mental health and substance use disorders. She has published her work widely in the areas of addiction, mental health, health services, and evaluation research. Dr. Grella directs the NIDA-funded pre- and post-doctoral training program at ISAP and is a Co-Investigator and Director of the Research and Methods Support Core of the NIDA-funded Center for Advancing Longitudinal Drug Abuse Research (CALDAR).

### Elizabeth A. Hall, Ph.D.

Elizabeth A. Hall, Ph.D., is a researcher in UCLA Integrated Substance Abuse Programs’ Criminal Justice Research Group. She currently serves as Co-Investigator for “Using Incentives to Improve Parolee Participation and Attendance in Community Treatment” (NIDA, PI: Prendergast). She was Principal Investigator for “Modeling Risk and Protective Factors for Well-being of Maltreated Youth” (NICHD) and Project Manager for “Criminal Justice Drug Abuse Treatment Studies-2” (NIDA, PI: Prendergast). Over more than 15 years of substance abuse research, Dr. Hall has been involved in a variety of research and evaluation projects examining substance abuse treatment outcomes. Her areas of expertise include contingency management in substance abuse treatment settings, and substance abuse treatment for women, individuals in the criminal justice system, and families in the child welfare system. Dr. Hall is the author of Staying in Touch: A Fieldwork Manual of Tracking Procedures for Locating Substance Abusers in Follow-up Studies, 2nd Edition, and provides training throughout the United States on follow-up techniques with substance-abusing populations. Dr. Hall is an instructor at Loyola Marymount University Extension and has served as an adjunct professor at the University of Southern California. Previously, she was a Senior Associate at IOX Assessment Associates, where she provided technical assistance in evaluation to school districts and state boards of education throughout the nation. In addition, she conducted large-scale evaluations of prevention programs for the Centers for Disease Control Division of Adolescent and School Health, the California Department of Health Services, and the California Wellness Foundation. Dr. Hall’s research interests include improving long-term outcomes for women offenders and their children, improving drug treatment services and effectiveness for criminal justice and child welfare populations, and qualitative and longitudinal study methodology.

### Alison B. Hamilton, Ph.D., M.P.H.

Alison B. Hamilton, Ph.D., M.P.H., is an Associate Research Anthropologist in the UCLA Department of Psychiatry and Biobehavioral Sciences. Her main area of interest is the relationship between addiction, mental health, and sexuality among women. She recently completed the NIDA-funded “Women, Methamphetamine, and Sex” study (K01 DA017647), which utilized mixed methods to investigate women methamphetamine users’ sexual experiences and behaviors as they relate to their methamphetamine use and/or histories of trauma. Dr. Hamilton is also a Research Health Scientist and Lead of the Qualitative Methods Group at the VA Health Services Research & Development Center for the Study of Healthcare Innovation, Implementation & Policy, specializing in women veterans’ health, mental health services research, and implementation science. She was a fellow in the inaugural cohort (2010–2012) of the NIMH/VA Implementation Research Institute and she is on the editorial board of Implementation Science.

## Maureen P. Hillhouse, Ph.D.

Maureen Hillhouse, PhD., Research Psychologist. Dr. Hillhouse joined the UCLA Drug Abuse Research Center (now the Integrated Substance Abuse Programs) as a NIDA-funded pre-doctoral fellow in 1996, and completed her dissertation in the Department of Psychology at UCLA on the topic of adolescent substance abuse treatment in 1998. She remained at DARC/ISAP and served as Project Director for several research projects addressing treatment outcome, collaborated on publications, and was awarded a NIDA-funded B-start grant to study a developing cognitive model of recovery. Moving from psychosocial treatment outcomes research to clinical trials, Dr. Hillhouse’s current research is in the area of medication trials – testing medications for the treatment of substance use disorders. Recently completed projects include a NIDA-funded project examining psychosocial treatments added to pharmacotherapy with buprenorphine for opioid dependence, and a double-blind, placebo-controlled pharmacotherapy trial investigating treatment with methylphenidate for methamphetamine use disorders. As an investigator on the NIDA Clinical Trials Network in the Pacific Region Node under the direction of Dr. Walter Ling, Dr. Hillhouse has assisted in the development and conduct of several multi-site trials led by the Pacific Region Node, including a study investigating the safety and effectiveness of buprenorphine provided with naltrexone for the treatment of cocaine use disorders, and a trial examining the effectiveness of a combination medication for methamphetamine use disorders. Dr. Hillhouse also serves as a Committee Member for the UCLA South Campus Institutional Review Board and participates as a consultant for the Prism Awards, sponsored by NIDA and the Entertainment Industries Council.

### Yih-Ing Hser, Ph.D.

Dr. Yih-Ing Hser is Professor-in-Residence in the Department of Psychiatry and Behavioral Sciences at the UCLA Integrated Substance Abuse Programs and the Director of the Center for Advancing Longitudinal Drug Abuse Research. As a trained quantitative psychologist, she has extensive experience in health services research, treatment evaluation, and long-term follow-up research, derived from her prior and ongoing research projects.  She has been conducting research in the field of substance abuse and its treatment since 1980 and has extensive experience in research design and advanced statistical techniques applied to substance abuse data.  In addition to gender-related issues in substance abuse and treatment, Dr. Hser has published in the areas of treatment evaluation, epidemiology, natural history of drug addiction, and innovative statistical modeling development and application.

### David Huang, Dr.P.H.

Yu-Chuang (David) Huang, Dr.P.H, M.P.H., is currently serving as senior statistician at the UCLA Integrated Substance Abuse Programs. For the past 10 years, he has been actively involved in large health education and epidemiological research projects at UCLA. He has provided statistical support on several multi-center longitudinal studies examining health care for drug abuse patients in treatment institutes, and is responsible for planning and conducting all data management and statistical analyses, especially the choosing of appropriate methods for multivariate analyses. Recently, he has also expanded his research in conducting quantitative analyses of long-term follow-up data for adolescents and for drug users and has made a contribution to the “Center for Advancing Longitudinal Drug Abuse Research” project, which extensively explores life-course trajectories of drug use and risky health behaviors as well as the impact of mental disorders and chronic diseases. More recently, he has served as a Principal Investigator in a study funded by the National Institute of Mental Health that examines trajectories of sexual risk behaviors among adolescents and the association of such behaviors with mental health, substance use, and delinquency.

### Mitchell Karno, Ph.D.

Mitchell Karno, Ph.D. (Clinical Psychology, University of California, Santa Barbara, 1997) is Research Psychologist in UCLA’s Department of Psychiatry and is the Director of Alcohol Studies at ISAP. Dr. Karno's primary research areas include patient/treatment matching, mechanisms of behavior change for alcoholism, and screening for alcohol problems. Dr. Karno is currently Principal Investigator for the National Institutes of Health Career Development Award “Cognitive Neuroscience of Decision Making in Recovery from Alcoholism.” He is Co-Principal Investigator for a clinical trial examining a model of screening and brief intervention for risky substance use among patients in mental health treatment settings. Dr. Karno is also Co-Investigator on a screening and brief alcohol intervention study among Hispanic day laborers. Dr. Karno currently serves as Assistant Editor for the journal Addiction and is a standing member of the NIH/NIAAA Treatment and Health Services Initial Review Group.

## Sherry Larkins, Ph.D.

Sherry Larkins, Ph.D., has worked for Friends Research Institute and UCLA’s Integrated Substance Abuse Programs since 1998. She currently oversees ISAP’s International Training and Education efforts, and conducts co-occurring training and evaluation initiatives across the state. Prior to her current position, she directed training and technical assistance initiates for the Los Angeles County, Department of Mental Health. She’s led multiple epidemiological and clinical research studies, including ones that investigating the spread of HIV and other sexually transmitted infections among substance users, and others that focus on treatment interventions. She has been involved in substance abuse research for over 20 years and completed her doctorate in medical sociology at Rutgers University in 1999. Her research interests include stimulant abuse, substance abuse treatment for marginalized populations, sexual risk behaviors associated with substance use, and qualitative methodologies.

### Walter Ling, M.D.

Walter Ling, M.D., is Professor of Psychiatry and Founding Director of the Integrated Substance Abuse Programs (ISAP) at UCLA, one of the foremost substance abuse research groups in the United States and worldwide. He is board certified in neurology and psychiatry, is active in research and clinical work, and has been listed in “Best Doctors in America,” “Best Doctors in the West,” and “Best Doctors in Los Angeles.” Dr. Ling’s research in pharmacotherapy for opioid addiction provided pivotal information for the approval of LAAM, naltrexone, and buprenorphine. His current research includes opioid use disorders, opioid-induced hyperalgesia, treatment of pain in opioid-maintained patients (including those treated with buprenorphine and the role of buprenorphine in the management of pain in these patients), and examination of methylphenidate for methamphetamine dependence. The scope of ISAP’s research under Dr. Ling’s leadership has encompassed the development of pharmacotherapies and behavioral therapies for the treatment of substance use disorders involving opioids, cocaine, methamphetamine, alcohol, and nicotine. Dr. Ling has extended ISAP’s research beyond the United States to Asia and the Middle East, and he has led or participated in international training efforts in 15 countries to advance addiction medicine and addiction research. As Principal Investigator of the Pacific Region Node of the NIDA Clinical Trials Network (CTN), Dr. Ling recently completed a nationwide 11-site trial investigating the effectiveness of buprenorphine provided with extended-released naltrexone for reducing cocaine use in cocaine-dependent individuals who have a history of opioid use disorder, and is currently leading analysis efforts. Dr. Ling is currently directing another CTN clinical trial for the treatment of methamphetamine use disorders that will examine a novel stepped approach utilizing a medication combination and enhanced methods for confirming medication compliance. Dr. Ling’s current and future research projects will continue to examine potential and promising methods for the treatment of substance use disorders.

### Nena P. Messina, Ph.D.

Nena P. Messina, Ph.D., is a Criminologist at UCLA Integrated Substance Abuse Programs and has been involved in substance abuse research for over 14 years. Dr. Messina’s areas of expertise include the specialized treatment needs of drug-dependent women offenders and the association between crime, mental health, and substance abuse. Dr. Messina was appointed as a Special Consultant to act as a Governor’s Rehabilitation Strike Team Member to create a strategic plan to reform the California prison system in response to Legislative bill AB 900 - The Public Safety & Offender Rehabilitation Services Act of 2007. Dr. Messina has also focused her efforts toward identifying the long-term outcomes of drug-exposed children and children with incarcerated parents. Dr. Messina has a successful history as the Principal Investigator of several NIDA-funded grants and California state contracts assessing the effectiveness of gender-responsive treatment for women offenders (on parole, in prison, or under community supervision such as re-entry programs, drug court, and Prop 36). Dr. Messina has collaborated on numerous publications on the psychosocial correlates of substance abuse treatment outcomes and has contributed a great deal to the understanding of co-occurring disorders, trauma and abuse, and treatment responsivity for women offenders.

### Larissa J. Mooney, M.D.

Dr. Larissa Mooney is a board certified addiction psychiatrist with expertise in the treatment of substance use disorders and psychiatric comorbidity.  After obtaining residency training at New York University, she completed a fellowship in addiction psychiatry at Cedars-Sinai Medical Center in 2006. Dr. Mooney is an Assistant Clinical Professor of Psychiatry at UCLA and Director of the UCLA Addiction Medicine Clinic, where she supervises and teaches psychiatrists-in-training in both inpatient and outpatient clinical settings. She is active in the American Academy of Addiction Psychiatry (AAAP), where she serves on the Executive Board of Directors.  Since joining UCLA Integrated Substance Abuse Programs in 2007, Dr. Mooney has conducted research on treatment interventions for addictive disorders and has collaborated on community training initiatives to enhance understanding of substance abuse and concomitant psychiatric illness among mental health clinicians. She is a Co-Lead Investigator for the Pacific Region Node of the NIDA Clinical Trials Network. Her interests include development of psychopharmacological and integrated treatments for addiction and advancement of substance abuse training for health care professionals.

### Debra A. Murphy, Ph.D.

Debra A. Murphy (Ph.D. in Psychology, Florida State University, 1987) is a Professor-in-Residence and Director of the Health Risk Reduction Projects within UCLA ISAP. She has conducted HIV/AIDS behavioral research on children, adolescents, adults, and families over the past 21 years. Dr. Murphy is currently Principal Investigator on three NIMH-funded R01s. The first is a Collaborative R01 to conduct a multi-site (Los Angeles County and Atlanta, Georgia) trial of an intervention to assist mothers living with HIV (MLH) with disclosing their serostatus to their young (age 6 – 12 year old), well children. The second is to assess the impact of maternal HIV/AIDS on late adolescent/early adult children in what will be a 15-year longitudinal study, as she has followed these families since the children were 6 to 11 years of age.  The third is to test the preliminary efficacy of a parenting intervention for HIV-infected mothers with well children aged 6 to 14 years old. Overall, Dr. Murphy has been the P.I. on nine federally funded grants and three state-funded grants, as well as a Co-Investigator on 18 federally funded projects. Prior to coming to UCLA, she was the Associate Director for the Center for AIDS Intervention in Wisconsin, and Co-Investigator on a series of federal grants focused on outcome evaluations of HIV behavioral risk-reduction interventions.

### ****Deborah Podus****, Ph.D.

**Deborah Podus**, Ph.D., is an Associate Research Sociologist at UCLA ISAP whose primary research interests are treatment effectiveness and substance abuse treatment policy. Dr. Podus has conducted numerous policy and treatment-related projects at ISAP including, most recently, research on disaster preparedness for disruptions in methadone treatment and research on migration and substance abuse among first-generation Mexican migrants. Other studies have focused on the intersection between substance abuse and welfare reform, research on the impact of the termination of SSI benefits to persons disabled by substance abuse, and research on methadone treatment regulation. She has also been Co-PI and project director for several meta-analyses on various aspects of drug abuse treatment. Her research has been funded by grants from the National Institute on Drug Abuse, the Robert Wood Johnson Foundation-Substance Abuse Policy Research Program, the Center for Substance Abuse Treatment (CSAT), the California Policy Research Center, and UC MEXUS. She has a doctorate in Sociology from Rutgers University and received postdoctoral training in mental health service systems and evaluation research at UCLA.

### Michael Prendergast, Ph.D.

Michael Prendergast, Ph.D., is Director of the Criminal Justice Research Group at UCLA ISAP. He has directed various projects studying drug treatment strategies in the criminal justice system. He has been Principal Investigator of evaluations of treatment programs in correctional settings in California: the Forever Free Treatment Program at the California Institution for Women, the California Substance Abuse Treatment Facility at Corcoran, and 15 treatment programs at other California prisons. He has also been Principal Investigator of several NIDA-funded studies: a 5-year follow-up study of participants in a prison-based therapeutic community, a study of the use of vouchers within a drug court treatment program, a study of the relative effectiveness of mixed-gender and women-only community treatment, a study of the of incentives to increase retention in a residential treatment program for parolees, and an evaluation of SBIRT with jail inmates.. He was Co-Principal Investigator of the statewide evaluation of the Substance Abuse and Crime Prevention Act (Proposition 36) and is currently Principal Investigator of the Pacific Coast Research Center of the NIDA-funded Criminal Justice Drug Abuse Treatment Studies (CJ-DATS). He has also conducted three meta-analyses on the effectiveness of drug abuse treatment. His research interests include treatment effectiveness, meta-analysis, treatment policy, issues in coerced treatment, and treatment for drug-abusing offenders. His work has been published in American Journal of Drug and Alcohol Abuse, American Journal of Public Health, Criminal Justice and Behavior, Drug and Alcohol Dependence, Journal of Drug Issues, Journal of Experimental Criminology, Journal of Offender Rehabilitation, and Prison Journal.

### Richard A. Rawson, Ph.D.

Richard A. Rawson, Ph.D., is Co-Director of UCLA Integrated Substance Abuse Programs and Professor-in-Residence at the UCLA Department of Psychiatry, in which he has been a member for more than 20 years. He received a Ph.D. in experimental psychology from the University of Vermont in 1974. Dr. Rawson oversees clinical trials on pharmacological and psychosocial addiction treatments. He is principal investigator of NIDA grants on aerobic exercise, screening and brief intervention in a mental health setting, and a Fogarty training grant between UCLA and Cairo University. He also is principal investigator of the SAMHSA/PEPFAR: Cooperative Agreement for Workforce Development in Vietnam: HIV-Addiction Technology Transfer Center and recently completed the SAMHSA/Department of State: Iraq Drug Demand Reduction Initiative. He has led addiction research and training projects for the United Nations, the World Health Organization, the Drosos Foundation, and the U.S. State Department, exporting science-based knowledge to many parts of the world. Dr. Rawson has published 3 books, 40 book chapters, and over 200 peer-reviewed articles and has conducted over 1,000 workshops, paper presentations, and training sessions.

### Cathy J. Reback, Ph.D.

Cathy J. Reback is a Research Sociologist with UCLA ISAP, a Senior Research Scientist with Friends Research Institute, Inc., and a Core Scientist with the UCLA Center for HIV Identification, Prevention and Treatment Services (UCLA CHIPTS). Dr. Reback’s research focuses on the intersection of sexual identity, gender identity, substance use, and HIV risk behaviors. Currently, Dr. Reback is Principal Investigator of a NIDA-funded study to evaluate differential immediate and sustained effects, and cost effectiveness, of transmitting theory-based text messages by peer health educators, versus by automation, compared to an assessment-only control condition among out-of-treatment, methamphetamine-using men who have sex with men (MSM) for reductions of methamphetamine use and HIV sexual risk behaviors; a NIDA-funded study to develop a methamphetamine-abuse treatment intervention cross-platform computerized mobile app for MSM to reduce their methamphetamine use and HIV sexual risk behaviors, and to increase antiretroviral therapy (ART) medication adherence; a HRSA-funded project to evaluate a multi-tiered model, integrating network (Social Network Recruitment), individual (Peer Health Navigation) and structural (Contingency Management) components to identify, recruit, test, link, treat, and retain transwomen of color into HIV care; and a CDC-funded project to adapt and transfer the Safety Counts evidence-based intervention for use among high-risk transgender women. Additionally, Dr. Reback currently serves as the Director of six County-funded contracts for high-risk MSM substance users and transgender women and three City-funded contracts. Dr. Reback has served as Principal Investigator or Co-Principal Investigator on mHealth, behavioral- and biobehavioral-intervention, ethnographic, and epidemiological studies funded by NIDA, HRSA, CDC, CSAT, CHRP, and the California State Office of AIDS. Dr. Reback has collaborated with Dr. Steve Shoptaw on major research intervention studies that evaluated behavioral therapies and HIV risk reduction for gay and bisexual male methamphetamine users. Dr. Reback’s community and policy work includes current and past membership on numerous local and national HIV/AIDS and substance abuse task forces and advisory committees.

## ****Traci Rieckmann****, Ph.D.

Traci Rieckmann, Ph.D., is an Adjunct Associate Professor in the UCLA Department of Psychiatry, and an Associate Professor in the School of Medicine, Department of Public Health & Preventive Medicine at Oregon Health & Science University. She received her Ph.D. in Counseling Psychology from the University of Utah, Salt Lake City, and she holds a M.S. in Health Promotion as well. As a clinician, clinical and policy researcher, organizational change consultant and educator, Dr. Rieckmann’s work impacts multiple service delivery settings.  Trained in both qualitative and quantitative methodologies, her specific research interests include acceleration of implementation of new practices including collaborative care models, technology-based interventions and medications to treat behavioral health and substance use disorders, organization and systems transformation, and quality improvement.  Dr. Rieckmann’s current research projects are focused on clinical trials for patients with addictions, disparities in care for American Indian/Alaska Native clients, and assessment of counselor and organizational attributes that drive uptake of evidence-based practices in substance abuse treatment, particularly medication-assisted treatment for opioid and alcohol dependence. Dr. Rieckmann is currently the Principal Investigator of the Northwest Addiction Technology Transfer Center, a behavioral health workforce capacity-building, SAMHSA-funded entity. She is also co-investigator on two NIH-funded studies: one examining the impact of the implementation of Coordinated Care Organizations in Oregon on treatment for alcohol and drug use disorders, and a second NIH-funded study on the use of buprenorphine to improve HIV care engagement and outcomes in Vietnam. Dr. Rieckmann has over 50 peer-reviewed publications, and presents on a regular basis at national and local conferences, and has provided legislative testimony regarding substance abuse policy in the state of Oregon. She is active in her local community and enjoys running, cycling, and outdoor activities with her family and friends.

## Marya T. Schulte, Ph.D.

Dr. Marya Schulte is a licensed clinical psychologist and Principal Investigator at UCLA Integrated Substance Abuse Programs.  She serves as the CALDAR Center Coordinator and conducts research in the area of technology-based interventions for teens and young adults. She received her doctoral degree from the SDSU/UCSD Joint Doctoral Program in Clinical Psychology and completed her internship and post-doctoral fellowship at VA Long Beach Healthcare System, focusing on treating veterans with substance use disorders and post-traumatic stress disorder. Subsequently, she worked at the VA Long Beach on a Department of Defense funded clinical trial examining the use of virtual reality in prolonged exposure with OEF/OIF veterans.  In addition to her work in adapting evidence-based interventions for an e-technology format to promote mHealth, her interests include the role of parents/guardians in adolescent treatment outcomes, gender differences in substance use trajectories, and barriers and facilitators for sustained recovery. She is currently the PI on a NIDA-funded study to develop a social media-based intervention aimed at reducing stigma and increasing treatment engagement and support among parents with adolescent children in substance abuse treatment.

### Cheryl Teruya, Ph.D.

Cheryl Teruya, Ph.D., is a researcher at the UCLA Integrated Substance Abuse Programs (ISAP).  She is currently working on the “Evaluation, Training, and Technical Assistance for Substance Use Disorder Services Integration” project (funded by the California Department of Health Care Services). Dr. Teruya was Principal Investigator for a NIDA-funded study exploring Proposition 36 as a turning point in life-course drug-use trajectories, Coordinator for the NIDA-funded Center for Advancing Longitudinal Research (CALDAR) at UCLA ISAP, and Co-Principal Investigator for a study examining treatment motivation among drug users. She has directed studies investigating the integration of behavioral health and primary care services in community-based health centers, the perspectives of providers and patients on barriers to and facilitators of retention among participants in  a multi-site clinical trial comparing buprenorphine/naloxone and methadone on liver function, treatment providers’ readiness for implementing research into practice, the impact of California’s Proposition 36 on the drug treatment system, and the potential effectiveness of a drum-assisted recovery therapy for Native Americans. In addition, Dr. Teruya led the qualitative study for the California Treatment Outcome Project (CalTOP), conducting and analyzing data from over 30 focus groups with community-based treatment providers throughout California and directed focus groups with county stakeholders as part of the Substance Abuse and Crime Prevention Act (SACPA) evaluation in California. Dr. Teruya has experience examining organizational change issues in public institutions and helping groups manage and deal with change in the corporate setting through workshops, teambuilding activities, and consultation. She has been conducting research at UCLA ISAP since 1999.

### Darren I. Urada, Ph.D.

Dr. Urada is Principal Investigator and co-investigator on multiple studies on the integration of substance use disorder (SUD) services with primary care and mental health, and the effect of the Affordable Care Act on SUD services. Previously, Dr. Urada also served as the Principal Investigator of California’s official statewide evaluation of the Substance Abuse and Crime Prevention Act of 2000 (aka, Proposition 36). Prior to this work he was principal investigator on a grant to convene an international meeting on the integration of SUD treatment with primary care that drew international experts from 23 countries as well as co-sponsorship from NIDA,SAMHSA, WHO, UNODC, and others. Dr. Urada’s other work has included serving as project director for the California State Treatment Needs Assessment Program and for a study on substance abuse and welfare reform, and contributing to the California Treatment Outcome Project (CalTOP), meta-analytic studies on substance use and HIV/AIDS, and research on treatment expansion. Dr. Urada also served as a relapse prevention group facilitator at an outpatient treatment clinic on a volunteer basis for about one year. He has worked for the UCLA Integrated Substance Abuse Programs since 1998. Dr. Urada has authored over 75 chapters, reports, and peer-reviewed journal articles.